Colorado Kidney Care is proud to support two clinical research divisions focused on improving the care of patients with chronic kidney disease. Theses divisions are identified as Denver Nephrology Research Division and CKC Research Division.
Denver Nephrology Research Division. Dr Geoffrey A Block created the Denver Nephrology Research Division (DNRD) in 1998 and serves as the Director of Clinical Research working closely with Dr. Laura Kooienga. Dr. Block and Dr. Kooienga share research interests that include bone health, mineral disorders related to calcium and phosphorous, anemia, diabetic kidney disease, genetic disorders including Alports and Fabry’s disease and cardiovascular disease with an emphasis on cardiovascular calcification. DNRD collaborates closely with investigators from many academic institutions including Harvard, Stanford, and Duke and with international colleagues from the United Kingdom, Netherlands, Germany, Italy, Spain, France and Australia. The research conducted at DNRD has been influential in changing the global care of patients with kidney disease and has been cited consistently by US and International Guideline Committees.
Dr. Block has served as the Principal Investigator on more than 90 clinical trials, serves on the Steering Committee for numerous national and international trials and has authored more than 85 peer-reviewed manuscripts. Dr. Block has served on several Technical Expert Panels for the Center for Medicare Services (CMS) and has been one of a select group of investigators from the United States to be invited to help develop international guidelines for the care of patients with chronic kidney disease.
Colorado Kidney Care (CKC) Research Division: The CKC Research Division is headed by Dr. Amber Podoll and includes Dr. Brad Marder and Dr. Alan Cooper. The Division’s focus is on immunologically mediated kidney diseases including system lupus glomerulonephritis, ANCA vasculitis, IgA nephropathy, and focal segmental glomerulosclerosis (FSGS). Patients with lupus related kidney disease are recruited for clinical trials from a multidisciplinary lupus nephritis clinic in collaboration with Dr. Sarah Young, Dr. Clancy Howard, and Rheumatologist, Dr. Joann Zell. Dr. Podoll’s other research interests include diabetic kidney disease and acute kidney injury in patients in the intensive care unit. Dr. Marder also studies the use of new immunomodulatory drugs in kidney transplant patients. The CKC Research Division’s goal is to change the course of kidney injury and improve patients’ quality of life.